AnyClip Media, a leading content marketing platform for distributing premium branded video, has announced a funding round of $21 million. The investment follows a $50 million investment and license agreement for another Jerusalem-based startup, Oramed Pharmaceuticals, and the acquisition of Qlight Nanotech.AnyClip-Logo

“I am excited AnyClip and its management team is getting the acknowledgment we deserve from leading investors,” said Oren Nauman, President and CEO of AnyClip Media. “With this additional funding, we will continue to build on our revolutionary technology platform to provide publishers, advertisers and content owners with the most advanced and secure solutions for effective global distribution of online video. Combined with the increased growth in mobile video and OTT solutions, we are positioned at the center of the fastest-growing sector of the advertising industry.”

Oren Nauman, CEO AnyClip
Oren Nauman, CEO AnyClip

New investors Ervington Investments (representing the interests of Russian businessman Roman Abramovich) and Limelight Networks (LLNW), a global leader in digital content delivery, as well as current shareholders Jerusalem Venture Partners, GTI, and other investors including business leaders Bob Pittman and former President and CEO of Sony Corporation of America Mickey Schulhof, participated in the expansion round.

Content owners, marketers, and advertisers use AnyClip to serve premium video to 40-80 million unique global consumers monthly.

“We are impressed by AnyClip’s leadership, cutting-edge technology built for all screens, and forward-looking vision for the future of online advertising,” said Gadi Tirosh, chairman of AnyClip Media and general manager of Jerusalem Venture Partners. “Oren and the team have built a powerful video platform that acts as a solution to the biggest problems advertisers currently face. The platform not only serves audiences with relevant, targeted videos but also ensures brands that the content will actually be seen by viewers in a brand-safe environment.”

Last week, Oramed Pharmaceuticals, a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced a non-binding Letter of Intent (LoI) for an investment and license agreement in China with Sinopharm Capital Management and Hefei Life Science & Technology Park Investments and Development. The deal is potentially valued at $50 million plus royalty payments.

And in a deal reportedly worth tens of millions of dollars, German group Merck recently announced its acquisition of Jerusalem-based Qlight Nanotech. Merck also said it would keep its R&D center in Jerusalem at the Qlight headquarters.